When Thyroid Carcinoma Goes Bad: A Morphological and Molecular Analysis

Head and Neck Pathology

Volumn 9, Issue 1, 2015, Pages 16-23

  Papp, Sylvia ^a,b   Asa, Sylvia L ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angioinvasion; Epigenetics; Mutations; Rearrangements; Thyroid carcinoma

Indexed keywords

ADENOCARCINOMA; GENETICS; HUMAN; MUTATION; PATHOLOGY; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; HUMANS; MUTATION; THYROID NEOPLASMS;

EID: 84939981536     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-015-0619-z     Document Type: Article

References (35)

1. Albores-Saavedra J, Henson DE, Glazer E, et al. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype–papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18:1–7.
2. O’Neill CJ, Oucharek J, Learoyd D, et al. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist. 2010;15:146–56.
3. Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol. 2011;24:1545–52.
4. Brierley JD, Asa SL. Thyroid cancer. Chapter 11. In: Gospodarowicz MK, O’Sullivan B, Sobin L (Eds): Prognostic factors in cancer. Third edition, Wiley-Liss Inc. 2006;119–122.
5. The Cancer Genome Atlas ResearchNetwork. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90.
6. D’Avanzo A, Treseler P, Ituarte PHG, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer. 2004;100:1123–9.
7. Cheng S, Serra S, Mercado M, et al. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res. 2011;17:2385–94.
8. Asioli S, Erickson LA, Sebo TJ, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34:44–52.
9. Ghossein R. Encapsulated malignant follicular cell-derived thyroid tumors. Endocr Pathol. 2010;21:212–8.
10. Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations. Am J Clin Pathol. 2003;120:71–7.
11. Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histologic subtypes (encapsulated vs non-encapsulated infiltrative) reveals distinct BRAF and RAS mutations. Mod Pathol. 2010;23:1191–200.
12. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256–64.
13. Hannallah J, Rose J, Guerrero MA. Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma. Int J Endocrinol. 2013;Article ID 317487.
14. Asioli S, Erickson LA, Righi A, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol. 2010;23:1269–78.
15. Garcia-Rostan G, Sobrinho-Simões M. Poorly differentiated thyroid carcinoma: an evolving entity. Diagn Histopathol. 2011;17:114–23.
16. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev. 2006;6:292–306.
17. Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA. 2009;106:4519–24.
18. Namba H, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–7.
19. Nikiforova MN, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–404.
20. Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690–4.
21. Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer. 2002;2:543–9.
22. Park JY, Kim WY, Hwang TS, et al. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma. Endocr Pathol. 2013;24:69–76.
23. Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130:736–44.
24. Asa SL, Giordano TJ, LiVolsi VA. Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist? Thyroid. 2014;Online, ahead of print. PMID:25409450.
25. Volante M, Rapa I, Gandhi M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94:4735–41.
26. Eberhardt NL, Grebe SK, McIver B, et al. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol. 2010;321:50–6.
27. Kroll TG. Molecular rearrangements and morphology in thyroid cancer. Am J Pathol. 2002;160:1941–4.
28. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20:603–10.
29. Elliott DD, Sherman SI, Bisaidy NL, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008;39:15–20.
30. Kondo T, Zheng L, Liu W, et al. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res. 2007;67:5461–70.
31. Logan A, Black EG, Gonzalez AM, et al. Basic fibroblast growth factor: an autocrine mitogen of rat thyroid follicular cells? Endocrinology. 1992;130:2363–72.
32. St. Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005;146:1145–53.
33. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 2006;91:3667–70.
34. Khoo ML, Beasley NJ, Ezzat S, et al. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2002;87:1814–8.
35. Khoo ML, Ezzat S, Freeman JL, et al. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab. 2002;87:1810–3.